Literature DB >> 16927039

Tranylcypromine: new perspectives on an "old" drug.

Helge Frieling1, Stefan Bleich.   

Abstract

The irreversible inhibitor of monoamine oxidase, tranylcypromine, is a potent antidepressant, but its use is limited to special indications due to side effects and dietary restrictions. The antidepressant action of tranylcypromine is not completely explainable by its effects on monoamine oxidase. Tranylcypromine also leads to an increase in brain trace amines, which are believed to play a key role in the pathophysiology of depression. It also affects other pathophysiological pathways associated with depression. Tranylcypromine treatment leads to an up-regulation of GABA(B)-receptors and modulates the phospholipid metabolism, which is essential for normal brain function. These findings implicate that the efficacy of tranylcypromine as an antidepressant may be due to its multiple actions within the human brain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16927039     DOI: 10.1007/s00406-006-0660-8

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  64 in total

1.  Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro.

Authors:  W Zhang; T Kilicarslan; R F Tyndale; E M Sellers
Journal:  Drug Metab Dispos       Date:  2001-06       Impact factor: 3.922

2.  Beta-adrenoceptors and antidepressants: possible 2-phenylethylamine mediation of chronic phenelzine effects.

Authors:  D J McManus; D D Mousseau; P R Paetsch; T B Wishart; A J Greenshaw
Journal:  Biol Psychiatry       Date:  1991-12-01       Impact factor: 13.382

Review 3.  Omega-3 fatty acids in inflammation and autoimmune diseases.

Authors:  Artemis P Simopoulos
Journal:  J Am Coll Nutr       Date:  2002-12       Impact factor: 3.169

4.  The effects of some indolalkylamines on the uptake and release of 5-hydroxytryptamine in rat striatum [proceedings].

Authors:  G B Baker; I L Martin; P R Mtichel
Journal:  Br J Pharmacol       Date:  1977-09       Impact factor: 8.739

5.  Phospholipid metabolism and depression: the possible roles of phospholipase A2 and coenzyme A-independent transacylase.

Authors:  David F Horrobin
Journal:  Hum Psychopharmacol       Date:  2001-01       Impact factor: 1.672

6.  Studies on the behaviour of semicarbazide-sensitive amine oxidase in Sprague-Dawley rats treated with the monoamine oxidase inhibitor tranylcypromine.

Authors:  D H Fitzgerald; K F Tipton; G A Lyles
Journal:  J Neural Transm Suppl       Date:  1998

7.  Detection and quantitation of a ring-hydroxylated metabolite of the antidepressant drug tranylcypromine.

Authors:  G B Baker; D R Hampson; R T Coutts; R G Micetich; T W Hall; T S Rao
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

8.  Displacement of serotonin from binding sites in rat cortex: the effects of biogenic "trace" amines.

Authors:  R A Locock; G B Baker; R T Coutts; W G Dewhurst
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1984       Impact factor: 5.067

9.  Effects of stress and tranylcypromine on amphetamine-induced locomotor activity and GABA(B) receptor function in rat brain.

Authors:  S A Sands; S A Reisman; S J Enna
Journal:  Life Sci       Date:  2003-01-17       Impact factor: 5.037

10.  Effects of chronic antidepressant treatment on dopamine-related [3H]SCH 23390 and [3H]spiperone binding in the rat striatum.

Authors:  P R Paetsch; A J Greenshaw
Journal:  Cell Mol Neurobiol       Date:  1992-12       Impact factor: 5.046

View more
  16 in total

Review 1.  Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.

Authors:  Katrina J Falkenberg; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2014-08-18       Impact factor: 84.694

Review 2.  Toward development of epigenetic drugs for central nervous system disorders: Modulating neuroplasticity via H3K4 methylation.

Authors:  Emily L Ricq; Jacob M Hooker; Stephen J Haggarty
Journal:  Psychiatry Clin Neurosci       Date:  2016-09-07       Impact factor: 5.188

Review 3.  The GABAβ receptor as a target for antidepressant drug action.

Authors:  Subroto Ghose; Michelle K Winter; Kenneth E McCarson; Carol A Tamminga; Salvatore J Enna
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

4.  Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction.

Authors:  Lihong Shi; Shuaiying Cui; James D Engel; Osamu Tanabe
Journal:  Nat Med       Date:  2013-02-17       Impact factor: 53.440

5.  Structural basis of drug binding to CYP46A1, an enzyme that controls cholesterol turnover in the brain.

Authors:  Natalia Mast; Casey Charvet; Irina A Pikuleva; C David Stout
Journal:  J Biol Chem       Date:  2010-07-28       Impact factor: 5.157

Review 6.  Exploring the multifactorial nature of autism through computational systems biology: calcium and the Rho GTPase RAC1 under the spotlight.

Authors:  Fares Zeidán-Chuliá; José Luiz Rybarczyk-Filho; Alla B Salmina; Ben-Hur Neves de Oliveira; Mami Noda; José Cláudio F Moreira
Journal:  Neuromolecular Med       Date:  2013-03-02       Impact factor: 3.843

7.  The trace amine theory of spontaneous hypertension as induced by classic monoamine oxidase inhibitors.

Authors:  Vincent Van den Eynde
Journal:  J Neural Transm (Vienna)       Date:  2021-08-09       Impact factor: 3.575

8.  Natural Polyphenols Inhibit Lysine-Specific Demethylase-1 in vitro.

Authors:  Arian Abdulla; Xiaoping Zhao; Fajun Yang
Journal:  J Biochem Pharmacol Res       Date:  2013-03-01

9.  Revisiting the monoamine hypothesis of depression: a new perspective.

Authors:  Joel S Goldberg; Clifton E Bell; David A Pollard
Journal:  Perspect Medicin Chem       Date:  2014-04-03

10.  Prostacyclin mediates endothelial COX-2-dependent neuroprotective effects during excitotoxic brain injury.

Authors:  Ying An; Natalya Belevych; Yufen Wang; Hao Zhang; Jason S Nasse; Harvey Herschman; Qun Chen; Andrew Tarr; Xiaoyu Liu; Ning Quan
Journal:  J Inflamm Res       Date:  2014-05-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.